CliffBio
small molecule

VIVIMUSTA

BENDAMUSTINE HYDROCHLORIDE

Loss of exclusivityJuly 2042latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameVIVIMUSTA
Active ingredientBENDAMUSTINE HYDROCHLORIDE
Strength100MG/4ML (25MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2022
Marketing statusRX

Listed patents

PatentExpiresType
12419867July 2042product
12208086July 2042product
11844784July 2042product
11707450July 2042product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VIVIMUSTA patent cliff — loss of exclusivity July 2042 | CliffBio